# A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.

> **NCT02094053** · PHASE2 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** E2020-Donepezil hydrochloride
- **DRUG:** E2020-Donepezil hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02094053
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-12
- **Primary completion:** 2016-09-16
- **Final completion:** 2017-04-21
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094053, "A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02094053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*